Literature DB >> 28072618

18F-FDG PET/CT Versus Contrast-Enhanced CT for Staging and Prognostic Prediction in Patients With Salivary Gland Carcinomas.

Marn Joon Park1, Jungsu S Oh, Jong-Lyel Roh, Jae Seung Kim, Jeong Hyun Lee, Soon Yuhl Nam, Sang Yoon Kim.   

Abstract

PURPOSE: Salivary gland carcinoma (SGC) is rare tumor with various histological type and metastatic potential. Pretreatment detection of metastases can contribute to planning the appropriate treatment of SGC. Therefore, the present study evaluated the utility of F-FDG PET/CT versus contrast-enhanced CT for detection of metastases and prediction of outcomes in SGC patients.
METHODS: Sixty-seven consecutive SGC patients who were prospectively evaluated by F-FDG PET/CT and contrast-enhanced CT and subsequently underwent surgery with or without postoperative radiotherapy/chemoradiotherapy were included. The diagnostic values of both imaging modalities for detection of metastatic diseases were compared with McNemar test and logistic regression using generalized estimating equations. Cox proportional hazard modeling was used to assess the prognostic values of the quantitative metabolic measurements detected by F-FDG PET/CT and of other clinical factors.
RESULTS: Among 67 SGC patients, 17 (25.4%) had cervical metastasis, and 4 (6%) had distant metastasis at initial staging. The sensitivity of F-FDG PET/CT for detection of cervical metastasis was significantly higher than those of CT (P < 0.05), and those of F-FDG PET/CT and CT for detection of distant metastasis did not differ (P > 0.5). Regional and distant site metastases were most reliably predicted by high-grade pathological analysis (P < 0.05). Extranodal extension and metabolic tumor volume measured by F-FDG PET/CT were independent predictors of progression-free survival and overall survival (all P < 0.05).
CONCLUSIONS: In SGC patients, F-FDG PET/CT detected metastatic diseases with high sensitivity and specificity, and metabolic tumor volumes helped to predict survival outcomes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28072618     DOI: 10.1097/RLU.0000000000001515

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

1.  Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma.

Authors:  Turki M Almuhaimid; Won Sub Lim; Jong-Lyel Roh; Jungsu S Oh; Jae Seung Kim; Soo-Jong Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-06       Impact factor: 4.553

2.  Diagnostic and Prognostic Utility of 18F-FDG PET/CT in Recurrent Salivary Gland Cancers.

Authors:  Reiko Nakajima; Snehal G Patel; Nora Katabi; Stephanie Flukes; Audrey Mauguen; Ian Ganly; Heiko Schöder
Journal:  AJR Am J Roentgenol       Date:  2021-04-07       Impact factor: 6.582

3.  Clinical use of 18F-FDG PET/CT in the differential diagnosis of patients with primary and secondary adenoid cystic carcinoma of the lung: a retrospective cohort study.

Authors:  Xiaolin Sun; Weiqing Gu; Hui Yuan; Siyun Wang; Yang Yang; Laura Evangelista; Liyan Zhang; Lei Jiang
Journal:  Transl Lung Cancer Res       Date:  2022-08

4.  Contemporary Management of Benign and Malignant Parotid Tumors.

Authors:  Jovanna Thielker; Maria Grosheva; Stephan Ihrler; Andrea Wittig; Orlando Guntinas-Lichius
Journal:  Front Surg       Date:  2018-05-11

5.  18F-fluorodeoxyglucose positron emission tomography-computed tomography as a screening tool for second primary cancers in cancer patients.

Authors:  Yang Liu; Jie Ma; Yingxin Liu
Journal:  Oncotarget       Date:  2017-09-30

6.  Distant metastases and synchronous malignancies on FDG-PET/CT in patients with head and neck cancer: a retrospective study.

Authors:  Lennart Flygare; Amal Al-Ubaedi; Wilhelm Öhman; Susanna Jakobson Mo
Journal:  Acta Radiol       Date:  2020-01-05       Impact factor: 1.990

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.